Inari Medical, Inc. (NASDAQ:NARI) Shares Bought by Motley Fool Asset Management LLC

Motley Fool Asset Management LLC grew its holdings in shares of Inari Medical, Inc. (NASDAQ:NARI) by 46.2% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 64,677 shares of the company’s stock after purchasing an additional 20,438 shares during the period. Motley Fool Asset Management LLC owned approximately 0.11% of Inari Medical worth $3,103,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. boosted its stake in Inari Medical by 6.9% during the fourth quarter. Vanguard Group Inc. now owns 5,038,292 shares of the company’s stock valued at $327,086,000 after buying an additional 325,586 shares in the last quarter. Brown Advisory Inc. boosted its stake in Inari Medical by 17.6% during the fourth quarter. Brown Advisory Inc. now owns 1,702,113 shares of the company’s stock valued at $110,501,000 after buying an additional 255,182 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Inari Medical by 7.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 596,007 shares of the company’s stock valued at $38,693,000 after buying an additional 41,555 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Inari Medical by 23.4% during the fourth quarter. Principal Financial Group Inc. now owns 567,266 shares of the company’s stock valued at $36,827,000 after buying an additional 107,622 shares in the last quarter. Finally, Norges Bank acquired a new position in shares of Inari Medical in the 4th quarter valued at $29,491,000. 90.98% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on NARI shares. Wells Fargo & Company dropped their price target on Inari Medical from $100.00 to $84.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 1st. Needham & Company LLC dropped their price target on Inari Medical from $72.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Truist Financial lifted their price target on Inari Medical from $47.00 to $60.00 and gave the stock a “hold” rating in a research note on Tuesday. Canaccord Genuity Group dropped their price target on Inari Medical from $75.00 to $55.00 and set a “buy” rating on the stock in a research note on Wednesday, May 1st. Finally, Piper Sandler dropped their price target on Inari Medical from $55.00 to $50.00 and set a “neutral” rating on the stock in a research note on Wednesday, May 1st. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $66.86.

Inari Medical Stock Performance

Shares of Inari Medical stock traded up $0.64 during trading on Wednesday, hitting $58.62. 997,200 shares of the stock traded hands, compared to its average volume of 1,041,962. The stock has a market cap of $3.41 billion, a P/E ratio of -141.41 and a beta of 1.01. Inari Medical, Inc. has a twelve month low of $36.73 and a twelve month high of $71.85. The company has a fifty day moving average price of $48.25 and a two-hundred day moving average price of $49.31.

Inari Medical (NASDAQ:NARI) last announced its quarterly earnings results on Tuesday, April 30th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.15). The firm had revenue of $143.19 million for the quarter, compared to analyst estimates of $138.32 million. Inari Medical had a negative net margin of 4.54% and a negative return on equity of 1.65%. On average, equities research analysts expect that Inari Medical, Inc. will post -0.41 EPS for the current fiscal year.

Insider Activity

In related news, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the sale, the chief executive officer now directly owns 465,474 shares in the company, valued at approximately $23,273,700. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In related news, CEO Andrew Hykes sold 3,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the sale, the chief executive officer now directly owns 465,474 shares in the company, valued at approximately $23,273,700. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Mitch C. Hill sold 6,000 shares of the business’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $45.97, for a total value of $275,820.00. Following the completion of the sale, the chief financial officer now owns 181,294 shares of the company’s stock, valued at $8,334,085.18. The disclosure for this sale can be found here. Insiders sold a total of 198,293 shares of company stock worth $9,543,468 in the last three months. 10.60% of the stock is owned by insiders.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.